Biosplice Therapeutics
Novel small-molecule therapeutics targeting osteoarthritis and degenerative disease
Biotech
📍 San Diego, CA
Founded 2008
Current Valuation
$12B
as of 2018-Q3
DECACORN
Biosplice Therapeutics (formerly Samumed) is a clinical-stage biotech developing small-molecule therapeutics that target the Wnt signaling pathway, with lead candidate lorecivivint for knee osteoarthritis. The company has not raised since 2018 and its $12.4B valuation reflects pre-Phase-III peak rather than current market pricing.
Company Profile
Growth
Clinical-stage; no commercial product approved
Last Round
Series E — $438M (Aug 2018) · Lead: Vickers Venture Partners
IPO Status
no imminent plans
Founders & Key People
Osman Kibar
Investors
Vickers Venture Partners · Hatteras Venture Partners · IKEA family office
Products
- Lorecivivint (osteoarthritis Phase III)
- Wnt-pathway drug pipeline
Competitors
Eli Lilly · Pfizer · Calibr (Scripps)
BiotechOsteoarthritisDecacornPre-Revenue
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2018-Q3. Refreshed quarterly.